As a point of convergence for many oncogenic signalling pathways, STAT3 is constitutively activated at high frequency in a wide diversity of cancers including lung cancer (Sen et al., 2020) and is a promising molecular target for cancer therapy (Niu et al., 2005). The gene discussed is STAT3; the disease is lung carcinoma.